In September 1969, they set up a Trial Research Group, which included law professors, medical researchers (including Harada), sociologists and even Michiko Ishimure to provide useful material to the lawyers to improve their legal arguments. Their report, Corporate Responsibility for Minamata Disease: Chissos Illegal Acts, published in August 1970, formed the basis of the ultimately successful lawsuit.The trial lasted almost four years. The litigation groups lawyers sought to prove Chissos corporate negligence. Three main legal points had to be overcome to win the case. First, the lawyers had to show that methylmercury caused Minamata disease and that the companys factory was the source of pollution. The extensive research by Kumadai and the governments conclusion meant that this point was proved quite easily. Second, they needed to show that Chisso could and should have anticipated the effect of its wastewater and taken steps to prevent the tragedy (i.e., was the company negligent in its duty of care). Third, it had to disprove that the "sympathy money" agreement of 1959, which forbade the patients from claiming any further compensation, was a legally binding contract. The trial heard from patients and their families, but the most important testimony came from Chisso executives and employees. The most dramatic testimony came from Hosokawa, who spoke on 4 July 1970 from his hospital bed where he was dying of cancer. Hosokawa explained his experiments with cats, including the infamous "cat 400", which developed Minamata disease after being fed factory wastewater.
Codeine/paracetamol, also known as codeine/acetaminophen and co-codamol, is a compound analgesic consisting of a combination of codeine phosphate and paracetamol (acetaminophen). Codeine/paracetamol is used for the relief of mild to moderate pain when paracetamol or non-steroidal anti-inflammatory drug (NSAIDs) such as ibuprofen, aspirin or naproxen alone do not sufficiently relieve symptoms.In 2019, it was the 173rd most commonly prescribed medication in the United States, with more than 3 million prescriptions. Combination products containing codeine are available over the counter in Barbados, United Kingdom, Israel and Costa Rica. Of the European Union (EU) member states, 12 countries (Bulgaria, Cyprus, Denmark, Estonia, France, Ireland, Latvia, Lithuania, Malta, Poland, Romania, Slovenia) allow the sale of OTC codeine solid dosage forms. Side effects
The most common side effects of co-codamol are constipation and feeling sick (nausea) or sleepy. Other side effects may include blood from mouth, skin rashes, dizziness, sedation, shortness of breath, hypersensitivity reaction, fainting (syncope or near syncope), confusion, loss of short-term memory, changes in blood, allergic reactions, euphoria, dysphoria, abdominal pain, itchiness, easy bruising, bleeding gums, vivid dreams, dry mouth and addiction.Genetic differences between people give rise to differing rates of metabolism of codeine to morphine. In about 5% of people this may happen particularly fast, leading to higher levels of morphine being passed through breast milk in amounts potentially able to cause fatal respiratory depression of a breastfed baby. References
External links
"Acetaminophen mixture with codeine phosphate". Drug Information Portal. U.S. National Library of Medicine.